Matthew Farley

Matthew Farley

Expertise: Fundamental Analysis, Technical Analysis

Education: Bachelor of Business Studies, Economics, Auckland University

Awards & Accomplishments: Financial Modeling & Valuation Analyst (FMVA)

Matthew Farley is a stock analyst and journalist who aims to bring a rational voice to the financial markets. He has written for publications such as the Motley Fool, Seeking Alpha, and New Scientist magazine, among others. Matthew has a particular interest in creating low-volatility portfolios and dividend investing.

Matthew spent most of his career in financial technology startups before he began writing about the markets in 2018. As such, he is long on cryptocurrencies and related Web 3.0 technologies, AI, large language models (LLM), and other disruptive platforms that are leading humanity forward.

Matthew’s investment philosophy is to build wealth slowly, preserve capital, and let compounding do the heavy lifting for you. As such, he owns shares in many blue-chip, established “boring” companies that have been around for decades with some adventurous incursions thrown into risky moonshots (as he’s still young).

Recent Articles

The 3 Most Undervalued Blockchain Stocks to Buy in May 2024

Discover three undervalued blockchain stocks poised for growth as the market navigates volatility and technological advancements in 2024.

The 3 Best EV Charging Stocks to Buy in May 2024

Discover three top EV charging stocks that stand out in May 2024, offering growth potential and great solutions in a changing market.

3 Materials Stocks to Sell in May Before They Crash & Burn

Discover three materials stocks to sell facing challenges in May 2024 due to market conditions, oversupply and rising costs.

7 Cannabis Stocks to Buy for a Smoking-Hot 2024

Ignite your portfolio with these seven sizzling cannabis stocks. From industry leaders to innovative upstarts.

The 3 Most Undervalued Lithium Stocks to Buy in May 2024

Undervalued opportunities in three lithium stocks with expansion plans are primed to surge as the market rebounds